This activity is no longer available for credit, however its content is still relevant for your educational needs.
Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with multiple myeloma (MM).

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• Describe optimal front-line treatment options for patients with newly diagnosed MM
• List therapeutic options for patients with relapsed/refractory MM
• Summarize key clinical data on the use of novel agents in the treatment of patients with MM as presented at the 2008 American Society of Hematology annual meeting
• Identify treatment considerations for older patients with newly diagnosed and relapsed MM

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Faculty Disclosures
Paul Richardson, MD, is on the advisory boards for Bristol-Myers Squibb, Celgene, Johnson & Johnson, and Millennium and has received research support from Millennium.

Jesús San-Miguel, MD is on the advisory board for Celgene, Janssen-Cilag, and Millennium.

Melissa Alsina, MD is on the advisory board for Celgene and Millennium.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.